Vor Biopharma Inc (VOR)

$2.14 +0.16 (8.08%)
Market Cap 271.10M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,701,800
Avg Vol 21,898,111
Day's Range N/A - N/A
Shares Out 126.68M
Stochastic %K 76%
Beta 2.06
Analysts Hold
Price Target $1.18

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 17 at 6:55 PM
$ATNF $BSLK $TRIB $VOR pop it like it's hot
0 · Reply
jichunxin
jichunxin Aug. 16 at 6:31 PM
$ITRM Can we make a comeback like $VOR?
2 · Reply
Lohengrin72
Lohengrin72 Aug. 16 at 8:12 AM
$VOR more news might come:
0 · Reply
Sswerve
Sswerve Aug. 15 at 7:54 PM
$VOR Think they pulled the last rabbit out of the hat, no more PR’s left to pump. Shouldnt be long now .
2 · Reply
LabPsycho
LabPsycho Aug. 15 at 4:55 PM
$GBIO IMO, the stock market is screaming the USA is in an irrevocable collapse. Why…it all makes sense – here are some recent examples: $GBIO – dump 90% of your workforce, stock up 50% $IMRX - $300 million offering, no problem, stock up about 20% Not crazy enough? $EQ – drugs don’t seem to be panning out so well, so hey, lets transition from biotech to the garden variety crypto scam – stock up 100% Still makes sense to you? $VOR – Seems like their drugs were not compelling enough so lets just issue 700 Million warrants or so and buy a further along drug from China – stock up almost 2000% at one point in a few weeks. I would not be surprised to see GBIO go either the VOR route or the EQ route - BioCrypto. Yay. Nothing to see here folks…no signs or the future staring you in the face. Enjoy.
2 · Reply
Porto98
Porto98 Aug. 15 at 3:22 PM
$ABVE $APLD $BULL $LIDR $VOR
0 · Reply
Zkillerz323
Zkillerz323 Aug. 15 at 2:10 PM
$VOR been holding for a while… would love to see the 🌕🥴
0 · Reply
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 15 at 2:05 PM
$ATNF $BSLK $TRIB $VOR all same volume format... all will do the same...upsie daisies
0 · Reply
Praann
Praann Aug. 15 at 2:04 PM
$VOR it will go up soon
0 · Reply
Stockgirl99
Stockgirl99 Aug. 15 at 12:30 PM
$CETX Market cap is just over $4 million and the revenue is $58 million. Gross margins improved to 44% from 41%, and cash position strengthened to $8.15 million. $VOR $IVP $TGL
0 · Reply
Latest News on VOR
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 11:15 AM EDT - 4 days ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 13, 2025, 8:30 AM EDT - 4 days ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Aug 4, 2025, 8:30 AM EDT - 13 days ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 27 days ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:00 PM EDT - 4 weeks ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 4 weeks ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 5 weeks ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 6 weeks ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 6 weeks ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 7 weeks ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 7 weeks ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 3 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 5 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 6 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 6 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 7 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 8 months ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 8 months ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio to Participate in Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 7, 2023, 4:05 PM EST - 1 year ago

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Nov 2, 2023, 9:01 AM EDT - 1 year ago

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

Jul 5, 2023, 8:51 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CBUS LUCY

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Jun 9, 2023, 7:30 AM EDT - 2 years ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Mar 27, 2023, 3:13 PM EDT - 2 years ago

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Feb 16, 2023, 12:00 PM EST - 2 years ago

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Jan 19, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Jan 12, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Dec 7, 2022, 7:45 AM EST - 2 years ago

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Dec 7, 2022, 7:30 AM EST - 2 years ago

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Nov 10, 2022, 4:15 PM EST - 3 years ago

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Vor Bio Appoints Eyal C. Attar, M.D.

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Appoints Eyal C. Attar, M.D.

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Oct 11, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Sep 28, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Aug 11, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 17 at 6:55 PM
$ATNF $BSLK $TRIB $VOR pop it like it's hot
0 · Reply
jichunxin
jichunxin Aug. 16 at 6:31 PM
$ITRM Can we make a comeback like $VOR?
2 · Reply
Lohengrin72
Lohengrin72 Aug. 16 at 8:12 AM
$VOR more news might come:
0 · Reply
Sswerve
Sswerve Aug. 15 at 7:54 PM
$VOR Think they pulled the last rabbit out of the hat, no more PR’s left to pump. Shouldnt be long now .
2 · Reply
LabPsycho
LabPsycho Aug. 15 at 4:55 PM
$GBIO IMO, the stock market is screaming the USA is in an irrevocable collapse. Why…it all makes sense – here are some recent examples: $GBIO – dump 90% of your workforce, stock up 50% $IMRX - $300 million offering, no problem, stock up about 20% Not crazy enough? $EQ – drugs don’t seem to be panning out so well, so hey, lets transition from biotech to the garden variety crypto scam – stock up 100% Still makes sense to you? $VOR – Seems like their drugs were not compelling enough so lets just issue 700 Million warrants or so and buy a further along drug from China – stock up almost 2000% at one point in a few weeks. I would not be surprised to see GBIO go either the VOR route or the EQ route - BioCrypto. Yay. Nothing to see here folks…no signs or the future staring you in the face. Enjoy.
2 · Reply
Porto98
Porto98 Aug. 15 at 3:22 PM
$ABVE $APLD $BULL $LIDR $VOR
0 · Reply
Zkillerz323
Zkillerz323 Aug. 15 at 2:10 PM
$VOR been holding for a while… would love to see the 🌕🥴
0 · Reply
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 15 at 2:05 PM
$ATNF $BSLK $TRIB $VOR all same volume format... all will do the same...upsie daisies
0 · Reply
Praann
Praann Aug. 15 at 2:04 PM
$VOR it will go up soon
0 · Reply
Stockgirl99
Stockgirl99 Aug. 15 at 12:30 PM
$CETX Market cap is just over $4 million and the revenue is $58 million. Gross margins improved to 44% from 41%, and cash position strengthened to $8.15 million. $VOR $IVP $TGL
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 15 at 2:15 AM
Fun Friday Watchlist Pt.8 $LIDR $ABVE $VOR $BULL $APLD Let's See Some Popping Price Action 📈🥂
0 · Reply
Cankles_McTaco_Tits
Cankles_McTaco_Tits Aug. 15 at 12:09 AM
$ATNF $BSLK $TRIB $VOR $FOSL
0 · Reply
NYS009
NYS009 Aug. 14 at 7:30 PM
$NVAX $VOR $OPEN $CTMX foh
0 · Reply
Roumieh91
Roumieh91 Aug. 14 at 7:14 PM
$VOR AH run ?
0 · Reply
Meksss
Meksss Aug. 14 at 6:54 PM
$CTMX $NVAX $OPEN $VOR today was good
0 · Reply
deerix
deerix Aug. 14 at 6:52 PM
$NVAX Am i wrong from time to time sure. But after having spectacular Q2 results on stocks like $VOR (1400%), $OPEN (600+%), $CTMX (370%), and MANY MORE I feel confident is ever. With results like this, it is more than ok to have some 10-15% losses on some stocks. That is trading. Nothing more, nothing less. My specialty, I catch ideas/gems when nobody is talking about them. Most recent call with $OPEN proves this, buying and posting my entry multiple times at 0.55 For transparent stock ideas, feel free to follow! ✅️⬇️
1 · Reply
Sswerve
Sswerve Aug. 14 at 1:59 PM
$VOR Guess the market is realizing that this extremely promotional Phase 3 trial PR was done in China and has little no impact on it being accepted in America. Usually a biotech doubles /triples on stage 3 success. This PR was timed to provide exit liquidity, won't be surprised if there's another offering out of the blue soon
1 · Reply
rambo222
rambo222 Aug. 14 at 1:46 PM
$VOR Shorts won't let this go anywhere and the further we get from yesterday's PR and the closer we get to the shareholders' meeting to vote on a rs, the more it'll drop. This is the new Nasdaq where shorting prevails over investing. Garbage.
0 · Reply
im_ichiban
im_ichiban Aug. 14 at 1:43 PM
$NEGG Chinese scam ready to tank $BABA $VOR $NNNN
0 · Reply
PrivateTrading
PrivateTrading Aug. 14 at 11:39 AM
$VOR Why would Remegen license a drug to Vor? Vor restructured and laid off most of their employees. I would figure Remegen could find a partner with more resources. Is Remegen responsible for all P3 and NDA costs?
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Vor Biopharma ( $VOR ), setting the rating to Buy with a target price of 3.
0 · Reply
StockGuru95
StockGuru95 Aug. 14 at 8:08 AM
$VOR premarket starts green and promising 🤝🚀
1 · Reply